Posters

The changes of retinal thickness following intravitreal bevacizumab,aflibercept, and triamcinolone intravitreal injections in eyes with Exudative Age-Related Macular Degeneration (clinical case).

Poster Details

First Author: M.Dunaieva UKRAINE

Co Author(s):                                 

Abstract Details



Purpose:

To evaluate retinal thickness changes following intravitreal bevacizumab, aflibercept and triamcinolone acetonide intravitreal injection for Treatment for Exudative Age-Related Macular Degeneration.

Setting:

The patient is 64 year-old man with dry AMD in the left eye and wet AMD in the left eye.

Methods:

The visual acuity in the right eye has worsened since 2 weeks. Retinal thickness was measured using optical coherence tomography at fovea and parafoveal areas. Changes in retinal thickness following treatment were compared statistically.

Results:

Retinal thickness decreased following bevacizumab injection and following aflibercept injection was not significant (17.8 μm and 27.0 μm), and only after triamcinolone IV the retinal thickness revealed a significant reduction (52.5 μm).

Conclusions:

Anti-VEGF therapy in the first line treatment of Exudative Age-Related Macular Degeneration. But corticosteriods can also reduce retinal thickness and intravitreal injection may be successful in the treatment.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy